FDA sends peptide policy to White House — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA submitted a peptide "interim access policy" to the White House this week for review, per a government filing
- The submission, part of the RFK Jr.-led peptide push tracked by the Coalition to Strengthen America's Healthcare newsletter, moves the policy from agency drafting into White House review
Why it matters: The FDA's filing pushes the peptide access framework from regulatory drafting into formal White House review — a concrete procedural step that gives compounders, prescribers, and patients a near-term signal that rules around peptides are being actively reshaped at the executive level rather than left in agency limbo.
Ask SkimNews
